Drug Reverses Signs of Liver Disease in People Living with HIV | NIH: National Institute of Allergy and Infectious Diseases

Drug Reverses Signs of Liver Disease in People Living with HIV | NIH: National Institute of Allergy and Infectious Diseases

Tuesday, October 15, 2019 Drug Reverses Signs of Liver Disease in People Living with HIV Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study Researchers at the National Institutes of Health and their colleagues at Massachusetts General Hospital in Boston report that the injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV. The study was conducted by NIAID and the National Cancer Institute, and the findings were published in The Lancet HIV.